|
|
| Line 3: |
Line 3: |
| | <StructureSection load='6b0g' size='340' side='right'caption='[[6b0g]], [[Resolution|resolution]] 1.90Å' scene=''> | | <StructureSection load='6b0g' size='340' side='right'caption='[[6b0g]], [[Resolution|resolution]] 1.90Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6b0g]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Plafo Plafo]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6B0G OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6B0G FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6b0g]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Plasmodium_falciparum_NF54 Plasmodium falciparum NF54]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6B0G OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6B0G FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6azz|6azz]], [[6b08|6b08]], [[6b0a|6b0a]], [[6b0e|6b0e]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6b0g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6b0g OCA], [http://pdbe.org/6b0g PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6b0g RCSB], [http://www.ebi.ac.uk/pdbsum/6b0g PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6b0g ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6b0g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6b0g OCA], [https://pdbe.org/6b0g PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6b0g RCSB], [https://www.ebi.ac.uk/pdbsum/6b0g PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6b0g ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | + | == Function == |
| | + | [https://www.uniprot.org/uniprot/OS25_PLAFO OS25_PLAFO] |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 25: |
Line 27: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Plafo]] | + | [[Category: Plasmodium falciparum NF54]] |
| - | [[Category: Bosch, A]] | + | [[Category: Bosch A]] |
| - | [[Category: Julien, J P]] | + | [[Category: Julien JP]] |
| - | [[Category: King, C R]] | + | [[Category: King CR]] |
| - | [[Category: McLeod, B]] | + | [[Category: McLeod B]] |
| - | [[Category: Scally, S W]] | + | [[Category: Scally SW]] |
| - | [[Category: Antibody]]
| + | |
| - | [[Category: Egf-like domain]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Malaria]]
| + | |
| - | [[Category: Transmission blocking vaccine]]
| + | |
| Structural highlights
Function
OS25_PLAFO
Publication Abstract from PubMed
The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-blocking vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit parasite development when ingested by Anopheles mosquitoes during blood meals. The Pfs25 three-dimensional structure has remained elusive, hampering a molecular understanding of its function and limiting immunogen design. We report six crystal structures of Pfs25 in complex with antibodies elicited by immunization via Pfs25 virus-like particles in human immunoglobulin loci transgenic mice. Our structural findings reveal the fine specificities associated with two distinct immunogenic sites on Pfs25. Importantly, one of these sites broadly overlaps with the epitope of the well-known 4B7 mouse antibody, which can be targeted simultaneously by antibodies that target a non-overlapping site to additively increase parasite inhibition. Our molecular characterization of inhibitory antibodies informs on the natural disposition of Pfs25 on the surface of ookinetes and provides the structural blueprints to design next-generation immunogens.
Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.,Scally SW, McLeod B, Bosch A, Miura K, Liang Q, Carroll S, Reponen S, Nguyen N, Giladi E, Ramisch S, Yusibov V, Bradley A, Lemiale F, Schief WR, Emerling D, Kellam P, King CR, Julien JP Nat Commun. 2017 Nov 16;8(1):1568. doi: 10.1038/s41467-017-01924-3. PMID:29146922[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Scally SW, McLeod B, Bosch A, Miura K, Liang Q, Carroll S, Reponen S, Nguyen N, Giladi E, Ramisch S, Yusibov V, Bradley A, Lemiale F, Schief WR, Emerling D, Kellam P, King CR, Julien JP. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25. Nat Commun. 2017 Nov 16;8(1):1568. doi: 10.1038/s41467-017-01924-3. PMID:29146922 doi:http://dx.doi.org/10.1038/s41467-017-01924-3
|
